Weight gain in people living with HIV switched to dual therapy-Reference-Cited by-同舟云学术

Weight gain in people living with HIV switched to dual therapy

Published:2020-01-01 Issue:1 Volume:34 Page:155-157
ISSN:0269-9370
Container-title:AIDS
language:en
Short-container-title:

Author:

Vizcarra Pilar,Vivancos María J.,Pérez-Elías María J.,Moreno Ana,Casado José L.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Infectious Diseases,Immunology,Immunology and Allergy

Reference12 articles.

1. Body composition and adipokines changes after initial treatment with darunavir-ritonavir plus either raltegravir or tenofovir disoproxil fumarate-emtricitabine: a substudy of the NEAT001/ANRS143 randomised trial;Bernardino;PLoS One,2019

2. Dolutegravir and weight gain;Menard;AIDS,2017

3. Brief report: weight gain in persons with HIV switched from efavirenz-based to integrase strand transfer inhibitor-based regimens;Norwood;JAIDS J Acquir Immune Defic Syndr,2017

4. Switch to dolutegravir from a boosted protease inhibitor associated with significant weight gain over 48 weeks in NEAT-022, a randomised 96-week trial;Waters;J Int AIDS Soc,2018

5. HIV-associated lipodystrophy: from fat injury to premature aging;Caron-Debarle;Trends Mol Med,2010

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. In-depth Analysis of the HIV Reservoir Confirms Effectiveness and Safety of Dolutegravir/Lamivudine in a Phase 4 Randomized Controlled Switch Trial (RUMBA);The Journal of Infectious Diseases;2024-09-03

2. Protocol for the LIFEH project: a prospective observational study to explore lifestyle among people living with HIV experiencing weight gain, looking beyond antiretroviral therapy;BMJ Open;2024-09

3. Sex differences in the effectiveness and tolerability of dolutegravir plus rilpivirine as a switch strategy in people living with HIV;HIV Medicine;2024-02-20

4. Risks of metabolic syndrome in the ADVANCE and NAMSAL trials;Frontiers in Reproductive Health;2023-09-18

5. Excessive Weight Gain: Current Antiretroviral Agents in Virologically Suppressed People with HIV;AIDS Research and Human Retroviruses;2022-10-01